“What will be important is to engage with the patient community, it will be a very important process to complement the science that we are doing and to engage with those ultimate end users. That is the beauty of having these conversations with the people who are going to eventually end up adopting the technology.”

Today's episode of The G Word is a little different. We are sharing a live recording of a recent discussion at the Public Policy Projects Global Genomics Conference between Chris Wigley, our CEO, and Dr Genya Dana, Global Head of Health Policy at Avellino.

In their conversation, they delved into all things policy, such as data, ethics and education as genomics comes into the mainstream of healthcare and society. They also discussed the importance of engaging with the participant community and Dr Genya Dana’s work in the Precision Medicine Department at the World Economic Forum.

"If we had the same immune system, all of us, then we would be extinct by now"

On todays episode of The G Word, our CEO, Chris Wigley, is joined with Professor, Sir Munir Pirmohamed, a British clinical pharmacologist and geneticist. Munir is also the NHS chair of Pharmacogenomics at the University of Liverpool. 

They discuss the importance of pharmaceutical drug development, understanding genome structures to better identify and predict diseases and how our lifestyle choices can lead to variation in how our genes  interact with drugs. They also delve into the complexity of pharmacogenomic decisions, discussing, taking into account both clinical and genomic factors. 

"We're taking the native DNA molecule that's actually from the cell and we're reading the sequence of that molecule. That comes with some tremendous, enormous benefits, but it also comes with it some huge challenges."

On today's episode of The G Word, we are joined by Parker Moss, our Chief Commercial Officer at Genomics England, and Greg Elgar, the Director of Sequencing Economic England.

They discuss techniques such as preparation ahead of sequencing itself and the logistics to get blood and tissue from humans into the sequencing lab in Cambridge. They also delve into the science of how sequencing itself works, what is needed for accurate sequencing and highlight and debate the implications of genomics, as well as, how it comes into the mainstream of health care and society.

“I Remember when I got to the stage to introduce Edwin Cuppen, who was the first speaker on the cancer Genomics track, and I was just… it’s happening! It’s happening! We did it!”

On today's episode of The G Word, we are joined by the chairs for scientific content at the  recent Genomics England Research Summit: Dalia Kasperaviciute, Head of Genomic Data Sciences for Rare Disease; Alona Sosinsky, Scientific Director for Cancer; Francisco Azuaje, Director of Bioinformatics, and Maxine Mackintosh, Programme Lead for Diverse Data, all at Genomics England.

They choose their picks of the Summit, some of their favourite moments, and how it felt to get together again with the genomics community under one roof. They also discuss how what they saw and heard highlights the power and implications of genomics, as it comes into the mainstream of health care and society.

"The vast majority of what we think of as human differences, cultural and linguistic, the act of categorization in science itself, I've come to see as fundamentally fraught and political."

On this week's episode we join Diksha Srivastava from our Diverse Data team, Ewan Birney from EMBL-EBI and special guest Angela Saini, a science journalist, broadcaster and the author of best selling books Geek Nation, Inferior, and Superior: The Return of Race Science, published in 2019. Angela's work has appeared in Science, Wired, The Guardian, The New Humanist and New Scientist. She is also a presenter on the BBC Radio.

They discuss about the history of race science, the use of language and its implications on genomics.

“It's critical that the general public understand that science is a long process, and that science is a process that often begins with the art of the feasible. […] We wouldn't be anywhere without computers, we wouldn't be anywhere without DNA sequencing methods. That not only gives me confidence, but it also makes me feel that there's an awful lot left to do.”

In this week’s episode of The G Word, our Chief Ecosystems and Partnership Officer Parker Moss is joined by Harold Varmus, who was previously the director of the National Institute of Health and of the National Cancer Institute and is currently the Lewis Thomas University Professor of Medicine at Weill Cornell Medicine and a senior associate at the New York Genome Center. He also won the 1989 Nobel Prize in Physiology or Medicine for discovery of the cellular origin of retroviral oncogenes with J. Michael Bishop.

Today they discuss cancer biology, the future of cancer research and the major questions that studying diverse ethnicities will uncover through genomics. Harold and Parker also discussed some of the big challenges of bringing molecular diagnostics and genomics into lower income countries and the technologies that are continuing to help explore functional genomics in cancer.

“Patients are absolutely firmly at the centre. That every day we get out of bed, with the patient and their caregivers and families, front of mind. […] You can't be successful in drug development and novel therapeutic development, without engaging the patient communities, as a partner and as a collaborator on the journey.”

In this week’s episode of The G Word, our CEO Chris Wigley is joined by Dr Annalisa Jenkins, non-Executive Director at Perspectrum Ltd, Oncimmune, AVROBIO, Affimed, COMPASS Pathways and Genomics England 

They discuss Annalisa’s background across life sciences and the role of genomics in development of diagnostics and therapeutics. They also discuss the importance of patient communities.

"The big realisation for me working in life sciences is if we didn't have [this] industry, to translate this amazing science that comes out of academic institutions into usable products, then we wouldn't be able to benefit as individuals."

We join Chris Wigley and special guest Tamsin Berry in today's episode of, The G Word. Tamsin is Partner at Population Health Partners, and former Director of the UK government’s Office for Life Sciences.

They discuss the importance of Life Sciences and what it is, focusing on the impact this particular research has on individual lives. They discuss how Tamsin became a part of the life science world and her journey to becoming Director of the Office of Life Sciences. They also discuss the importance of research funding and genome understanding.

“The whole area is going to be crucial for everything from monitoring waste, you can think about its use in monitoring biodiversity, such a key area for the future. You can think about the impact of the environment and on the changes in species across the world over time. This is going to be a ubiquitous area of societal discussion.”

In this week’s episode of The G Word, our CEO Chris Wigley is joined by Sir Patrick Vallance, the Government’s Chief Scientific Adviser and the Head of Government Science and Engineering.

They discuss Sir Patrick Vallance’s role and work in the government, the areas that genomics is starting to touch on beyond healthcare and the use of genomic data. They also discuss the role of legislation and societal dialogue, they touched on the impact of the pandemic and how genomic sequencing is crucial to understand the spread of COVID-19. Sir Patrick Vallance also raised the importance of monitoring biodiversity and the impact on the environment.

“Let's talk about patients. That's where we have to always begin. This is about patients. I was tremendously impressed with how much the patient advocacy groups had accomplished, that helped us make judgments that are really complex and very dangerous judgments. All that played into the success. Then, of course, it was very rapidly approved around the world.”

In this week’s episode of The G Word, Dr Richard Scott, our Chief Medical Officer, is joined by Dr Stanley Crooke, M.D., Ph.D., the founder, chairman of the board and Chief Executive Officer of n-Lorem.

In this episode, Dr Scott and Dr Crooke discuss the foundation of n-Lorem, the importance of patient advocacy groups and the spinal muscular atrophy treatment Spinraza. They also discussed the value of whole genome sequencing in newborn screening.